Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Glofitamab + Obinutuzumab for Non-Hodgkin's Lymphoma
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial will assess the effectiveness and safety of glofitamab and obinutuzumab in treating Follicular and Marginal Zone Lymphoma patients who have not been treated before.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.